Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver Kennedy, Mario Mandalà, Sara Valpione et al.|European Journal of Cancer|2022Cited by 51